Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 12-Month High – Still a Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares hit a new 52-week high during trading on Tuesday. The stock traded as high as $15.98 and last traded at $15.9760, with a volume of 417,025 shares traded. The stock had previously closed at $15.91.

Bayer Aktiengesellschaft Stock Up 0.4%

The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. The firm’s 50-day simple moving average is $13.54 and its 200 day simple moving average is $12.62. The company has a market cap of $62.76 billion, a P/E ratio of -34.72, a PEG ratio of 1.90 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Tuesday, November 3rd. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.02). Bayer Aktiengesellschaft had a positive return on equity of 16.34% and a negative net margin of 3.28%. The company had revenue of $11.25 billion for the quarter, compared to analyst estimates of $11.21 billion. On average, research analysts forecast that Bayer Aktiengesellschaft will post 1.29 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a German life sciences company headquartered in Leverkusen. Founded in 1863, it develops products and services in pharmaceuticals, consumer health and agriculture. Its Pharmaceuticals business offers prescription medicines, including treatments in areas such as cardiovascular disease, oncology, women’s health and eye care. Consumer Health sells nonprescription medicines and self-care products, with brands including Claritin, Aleve and One A Day. Through its Crop Science business, Bayer provides seeds, crop protection products and agricultural solutions for farmers.